fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-02-18
Biotech partner: Galapagos (Belgium) Morphosys (Germany)
Type of agreement: * R&D
* development
Compound: antibody therapeutics
Disease area: bone & joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis
Nature of the agreement: Galapagos and MorphoSys have expanded their antibody alliance in bone & joint diseases. They have agreed to add another antibody target to the alliance, thereby increasing the total number of programs to four. Their previous agreement has been concluded in November 2008 (See agreements).

As part of the initial agreement, three targets implicated in bone & joint diseases were selected for the collaboration. Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific in vitro and in vivo experiments.
In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development. Based on this, Galapagos and MorphoSys have now added a fourth antibody target to the alliance. The partners have prioritized the targets in order to maximize the value and IP position of the respective therapeutic antibody programs.

Go back to previous page